SC0T:F:F-Invesco Markets plc - Invesco STOXX Europe 600 Optimised Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 425.4

Change

+2.25 (+0.53)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-8.18 (-1.36%)

USD 111.88B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.48 (+0.91%)

USD 106.38B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 105.77B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 62.83B
VUSA:F Vanguard Funds Public Limited ..

-0.43 (-0.40%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.95 (+0.40%)

USD 51.55B
XJSE:F Xtrackers II - Japan Governmen..

-0.09 (-1.20%)

USD 43.00B
0ZC:F Zscaler Inc

+2.84 (+1.54%)

USD 37.92B
BSND:F Danone SA

N/A

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-2.42 (-1.79%)

USD 24.77B

ETFs Containing SC0T:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.02% 83% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.02% 82% B 73% C
Trailing 12 Months  
Capital Gain 12.73% 61% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.73% 58% F 53% F
Trailing 5 Years  
Capital Gain 43.47% 55% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.47% 55% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 8.14% 61% D- 60% D-
Dividend Return 8.14% 58% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.27% 74% C 93% A
Risk Adjusted Return 98.46% 89% A- 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike